Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Genitourinary 27Gastrointestinal 20Gynecologic 13Thoracic 10Head & Neck 9CNS 8Breast 6Lymphoid 5Other hematologic neoplasm 4Dermatologic 4Other solid neoplasm 3Sarcoma 2Other neoplasm 2Tumor-Agnostic 1Plasma cell 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Watchful Waiting × Tumor-Agnostic × Clear all
NCT06745024 2026-05-04

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NRG Oncology

Phase 3 Active not recruiting
280 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡